Category Archives: BioUtah News
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor BIIB122 (DNL151) in participants with LRRK2-associated Parkinson’s disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that […]
Canary Speech Named to the 2024 CB Insights’ List of the 50 Most Innovative Digital Health Startups
Canary Speech recognized for achievements in non-invasive diagnostics in the most promising private digital health companies across the globe.
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized
Fluidx Medical Announces First Tumor Patient Treated in Prospective, Multinational Trial
Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial
BioUtah Award Winners and Utah Rare Disease Advisory Council Take Center Stage at Utah Life Sciences Innovation Caucus
More than a dozen Utah legislators on Wednesday, November 20, held a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC) at the state capitol.
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types
EVŌQ Nano Expands Antimicrobial Medical Device Platform, Demonstrates Efficacy Across Multiple Device Applications
Four Integration Methods Aim to Combat Healthcare-Associated Infections & Improve Device Performance
SINTX TECHNOLOGIES AND NED MEDICAL PARTNER TO ADVANCE CUTTING-EDGE CERAMIC MICROSPHERE MEDICAL DEVICES FOR CANCER TREATMENT
SINTX TECHNOLOGIES AND NED MEDICAL PARTNER TO ADVANCE CUTTING-EDGE CERAMIC MICROSPHERE MEDICAL DEVICES FOR CANCER TREATMENT
First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities
First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities
